Albertsons reports loss due to opioid settlement

Albertsons has reported a fourth-quarter loss, primarily driven by a significant charge related to a new opioid settlement. This settlement is intended to resolve substantially all opioid-related legal claims against the company. The financial impact of this resolution has weighed heavily on the company's recent earnings report. While the settlement provides clarity on future liabilities, it has resulted in a substantial one-time expense. The company will now focus on moving past this legal issue and concentrating on its core business operations and future profitability.